Literature DB >> 33308254

Detection of SARS-CoV-2 pneumonia: two case reports.

Felix S Seibert1, Daniela Toma2, Frederic Bauer2, Krystallenia Paniskaki3, Moritz Anft3, Benjamin J Rohn2, Simon Wang2, Diana Racovitan2, Nina Babel2,3, Timm H Westhoff2.   

Abstract

BACKGROUND: Developing therapeutic strategies for a SARS-CoV-2 infection is challenging, but first the correct diagnosis has to be made. Unspecific upper and lower respiratory tract symptoms can be misleading; hence, a nasopharyngeal swab test with a real-time reverse-transcription-polymerase chain reaction is of great importance. However, early viral clearing jeopardizes a sound diagnosis of COVID-19. CASE
PRESENTATION: We report on two Caucasian patients who had negative pharyngeal swab tests at the onset of SARS-CoV-2 pneumonia. In one patient, the virus was not even detectable in bronchoalveolar lavage despite typical radiomorphologic changes.
CONCLUSIONS: Negative PCR findings in both the pharynx and bronchoalveolar lavage do not exclude COVID-19 pneumonia. Computed tomography is a crucial diagnostic prerequisite in this context.

Entities:  

Keywords:  COVID-19; SARS-CoV-2; Swab test

Year:  2020        PMID: 33308254     DOI: 10.1186/s13256-020-02551-1

Source DB:  PubMed          Journal:  J Med Case Rep        ISSN: 1752-1947


  4 in total

1.  Testing Clinical Prediction Models.

Authors:  Junfeng Wang; Yue Li
Journal:  JAMA       Date:  2020-11-17       Impact factor: 56.272

2.  Predictive performance of interferon-γ release assays and tuberculin skin tests - Authors' reply.

Authors:  Jiaru Yang; Zhenhua Ji; Yu Zhang; Peng Yue; Xin Xu; Wenjing Cao; Guozhong Zhou; Shiyuan Wen; Zhe Ding; Lianbao Li; Taigui Chen; Miaomiao Jian; Lisha Luo; Shiqi Luo; Jing Kong; Feng Wang; Fukai Bao; Aihua Liu
Journal:  Lancet Infect Dis       Date:  2020-11-25       Impact factor: 25.071

3.  Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial.

Authors:  Yanjun Zhang; Gang Zeng; Hongxing Pan; Changgui Li; Yaling Hu; Kai Chu; Weixiao Han; Zhen Chen; Rong Tang; Weidong Yin; Xin Chen; Yuansheng Hu; Xiaoyong Liu; Congbing Jiang; Jingxin Li; Minnan Yang; Yan Song; Xiangxi Wang; Qiang Gao; Fengcai Zhu
Journal:  Lancet Infect Dis       Date:  2020-11-17       Impact factor: 25.071

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.